DESTINY-GASTRIC04 clinical trial: Principal Investigator

Activity: Other activity typesOther


A phase 3 multicenter, 2-arm randomised, open label study of Trastuzumab Deruxtecan in subjects with Her2-positive metastatic and/or unresectable gastric or gastro-oesophageal junction (GEJ) adenocarcinoma subjects who have progressed on or after a trastuzumab-containing regimen.
Period17 Nov 202210 Mar 2023
Held atAstraZeneca Plc, United Kingdom
Degree of RecognitionInternational